Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 15, 2023 10:32am
210 Views
Post# 35497963

RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyJune 14, 2024 - "The [biopharma] industry is staring down a looming patent cliff like it’s a massive hurricane inching toward landfall. And the patent cliff not too far in the distance is set to be one of the most harrowing in history."

With the industry facing this onslaught of challenges, pharma companies are battening the hatches through increased partnerships [M&A] and at times, bigger deals. But as the Economist recently noted, surging demand for attractive drug candidates and companies is triggering soaring premiums in M&A."


https://www.pharmavoice.com/news/pharma-patent-cliff-Merck-Keytruda-Pfizer-Seagen-Humira/652914/
<< Previous
Bullboard Posts
Next >>